Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today
ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Analysis of the primary and secondary endpoints of the phase 2/3 ACTISAVE study showed no improved efficacy with glenzocimab
Key results from this study will be presented at ESOC on May 15,.
<ul>
<li>
<h5>€15.5 million raised</h5>
</li>
<li>
<h5>Market capitalisation of €75 million</h5>
</li>
<li>
<h5>French Tech 120 company</h5>
</li>
<li>
<h5>5<span>th</span> listing of a biotech company on Euronext Paris in 2021</h5>
</li>
</ul>